Halozyme to Participate in Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
TD Cowen Starts Halozyme Therapeutics (HALO) at Outperform, 'I Can See Your Halo…But I Never Really Had A Doubt'
February 29, 2024 5:30 AM ESTTD Cowen analyst Brendan Smith initiates coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Outperform rating and a price target of $54.00.
The analyst comments "HALOs well-validated ENHANZE technology is the gold standard in subcutaneous drug development. An expansive partnership portfolio is driving rapid... More
